SCHEMBL4182845

SCHEMBL4182845

CCc1n[nH]cc1-c1cc(O)c2ccc(OC)c(C)c2n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.34
KDM4E B2RXH2 5/20 0.34
ALDH1A1 P00352 3/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
POLB P06746 2/20 0.34
GAA P10253 1/20 0.34
LMNA P02545 4/20 0.33
TSHR P16473 2/20 0.33
MAPK1 P28482 2/20 0.33
PDE4D Q08499 1/20 0.33
PDE10A Q9Y233 1/20 0.33
RAD52 P43351 1/20 0.33
SMPD3 Q9NY59 1/20 0.32
HPGD P15428 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CCNB2 O95067 1/20 0.31
CCNE2 O96020 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4178311 0.91 PDE10A (0.35) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL4183205 0.88 KDM4E (0.33) MAPTKDM4EMEN1KMT2APOLB
SCHEMBL4185269 0.86 KDM4E (0.34) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL4178062 0.86 PDE4A (0.34) KDM4EALDH1A1POLBGAATSHR
SCHEMBL4191730 0.86 SLC10A2 (0.33) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL4187144 0.81 ALDH1A1 (0.38) MAPTKDM4EALDH1A1KMT2ALMNA
SCHEMBL4189834 0.78 MAPK1 (0.37) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL12070947 0.75 KDM4E (0.41) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL4177976 0.75 KMT2A (0.31) KDM4EKMT2AGAAPDE4DPDE10A
SCHEMBL996497 0.73 CCR1 (0.42) MAPTMEN1KMT2AGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009014730-A1 MACROCYCLIC SERINE PROTEASE INHIBITORS IDENIX PHARMACEUTICALS, INC. (US) 2009-01-29 WO disclosed